Research ExplorerPublicationsHigh population prevalence of cardiac troponin I measured by...

High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort

Standard

High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. / Zeller, Tanja; Tunstall-Pedoe, Hugh; Saarela, Olli; Ojeda, Francisco; Schnabel, Renate B; Tuovinen, Tarja; Woodward, Mark; Struthers, Allan; Hughes, Maria; Kee, Frank; Salomaa, Veikko; Kuulasmaa, Kari; Blankenberg, Stefan; MORGAM Investigators.

In: EUR HEART J, Vol. 35, No. 5, 02.2014, p. 271-281.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zeller, T, Tunstall-Pedoe, H, Saarela, O, Ojeda, F, Schnabel, RB, Tuovinen, T, Woodward, M, Struthers, A, Hughes, M, Kee, F, Salomaa, V, Kuulasmaa, K, Blankenberg, S & MORGAM Investigators 2014, 'High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort', EUR HEART J, vol. 35, no. 5, pp. 271-281. https://doi.org/10.1093/eurheartj/eht406

APA

Zeller, T., Tunstall-Pedoe, H., Saarela, O., Ojeda, F., Schnabel, R. B., Tuovinen, T., Woodward, M., Struthers, A., Hughes, M., Kee, F., Salomaa, V., Kuulasmaa, K., Blankenberg, S., & MORGAM Investigators (2014). High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. EUR HEART J, 35(5), 271-281. https://doi.org/10.1093/eurheartj/eht406

Vancouver

Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. EUR HEART J. 2014 Feb;35(5):271-281. https://doi.org/10.1093/eurheartj/eht406

Bibtex

@article{629af6d0767946da82419b0190b73dc3,
title = "High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort",
abstract = "AIMS: Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population.METHODS AND RESULTS: High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events.CONCLUSION: Troponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals.",
keywords = "Biomarkers/blood, Cardiovascular Diseases/blood, Cohort Studies, Female, Humans, Immunoassay/methods, Male, Middle Aged, Myocardial Infarction/blood, Prevalence, Risk Assessment, Scotland/epidemiology, Sex Distribution, Stroke/blood, Troponin I/blood",
author = "Tanja Zeller and Hugh Tunstall-Pedoe and Olli Saarela and Francisco Ojeda and Schnabel, {Renate B} and Tarja Tuovinen and Mark Woodward and Allan Struthers and Maria Hughes and Frank Kee and Veikko Salomaa and Kari Kuulasmaa and Stefan Blankenberg and {MORGAM Investigators}",
year = "2014",
month = feb,
doi = "10.1093/eurheartj/eht406",
language = "English",
volume = "35",
pages = "271--281",
journal = "EUR HEART J",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort

AU - Zeller, Tanja

AU - Tunstall-Pedoe, Hugh

AU - Saarela, Olli

AU - Ojeda, Francisco

AU - Schnabel, Renate B

AU - Tuovinen, Tarja

AU - Woodward, Mark

AU - Struthers, Allan

AU - Hughes, Maria

AU - Kee, Frank

AU - Salomaa, Veikko

AU - Kuulasmaa, Kari

AU - Blankenberg, Stefan

AU - MORGAM Investigators

PY - 2014/2

Y1 - 2014/2

N2 - AIMS: Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population.METHODS AND RESULTS: High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events.CONCLUSION: Troponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals.

AB - AIMS: Our aim was to test the prediction and clinical applicability of high-sensitivity assayed troponin I for incident cardiovascular events in a general middle-aged European population.METHODS AND RESULTS: High-sensitivity assayed troponin I was measured in the Scottish Heart Health Extended Cohort (n = 15 340) with 2171 cardiovascular events (including acute coronary heart disease and probable ischaemic strokes), 714 coronary deaths (25% of all deaths), 1980 myocardial infarctions, and 797 strokes of all kinds during an average of 20 years follow-up. Detection rate above the limit of detection (LoD) was 74.8% in the overall population and 82.6% in men and 67.0% in women. Troponin I assayed by the high-sensitivity method was associated with future cardiovascular risk after full adjustment such as that individuals in the fourth category had 2.5 times the risk compared with those without detectable troponin I (P < 0.0001). These associations remained significant even for those individuals in whom levels of contemporary-sensitivity troponin I measures were not detectable. Addition of troponin I levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic (P < 0.0001) and net reclassification (P < 0.0001). A threshold of 4.7 pg/mL in women and 7.0 pg/mL in men is suggested to detect individuals at high risk for future cardiovascular events.CONCLUSION: Troponin I, measured with a high-sensitivity assay, is an independent predictor of cardiovascular events and might support selection of at risk individuals.

KW - Biomarkers/blood

KW - Cardiovascular Diseases/blood

KW - Cohort Studies

KW - Female

KW - Humans

KW - Immunoassay/methods

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/blood

KW - Prevalence

KW - Risk Assessment

KW - Scotland/epidemiology

KW - Sex Distribution

KW - Stroke/blood

KW - Troponin I/blood

U2 - 10.1093/eurheartj/eht406

DO - 10.1093/eurheartj/eht406

M3 - SCORING: Journal article

C2 - 24104876

VL - 35

SP - 271

EP - 281

JO - EUR HEART J

JF - EUR HEART J

SN - 0195-668X

IS - 5

ER -